Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.60 |
| ▸ | GRAMD1A | Q96CP6 | 6/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997318 | 0.94 | CRBN (0.62) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL19585916 | 0.93 | DDB1 (0.64) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL19585318 | 0.88 | DDB1 (0.65) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL21997166 | 0.88 | DDB1 (0.59) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL34464383 | 0.88 | DDB1 (0.59) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL20811989 | 0.88 | DDB1 (0.62) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL30938338 | 0.88 | DDB1 (0.62) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL20812502 | 0.88 | DDB1 (0.62) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL20812204 | 0.86 | DDB1 (0.61) | DDB1CRBNGRAMD1ATNFIL1B | |
| SCHEMBL30772320 | 0.86 | CRBN (0.70) | DDB1CRBNGRAMD1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | DDB1 511/4885CRBN 39/4885GRAMD1A 4661/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | DDB1 2480/4885CRBN 79/4885GRAMD1A 4445/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885GRAMD1A 2556/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | DDB1 68/4885CRBN 322/4885GRAMD1A 2650/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885GRAMD1A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.